Biocon Biologics, a subsidiary of Biocon, on Monday said its biosimilar to treat certain inflammatory diseases is now available in the US market.
The company said HULIO (adalimumab) injection, a biosimilar to Humira (adalimumab), is now available to patients in the US after five years of experience in Europe and two years in Canada.
"The launch of HULIO, our biosimilar adalimumab, in the US, is an important milestone for Biocon Biologics as it expands our well-known biosimilar product offering to patients in the US," Biocon Biologics CEO and MD Shreehas Tambe said in a statement. This launch builds on the company's strong presence in oncology and diabetes, he added.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
